Lupin Ltd – Strategy, SWOT and Corporate Finance Report

Lupin Ltd – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company

Key Highlights

Lupin Ltd (Lupin) develops and manufactures generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). The company has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Japan, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Scope

Detailed information on Lupin Ltd required for business and competitor intelligence needs

A study of the major internal and external factors affecting Lupin Ltd in the form of a SWOT analysis

An in-depth view of the business model of Lupin Ltd including a breakdown and examination of key business segments

News about Lupin Ltd, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Lupin Ltd and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Lupin Ltd as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Lupin Ltds business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Sun Pharmaceutical Industries Ltd

Lincon Pharmaceuticals Ltd

Intas Pharmaceuticals Ltd

Dr. Reddy's Laboratories Ltd

Divi's Laboratories Ltd

Cipla Ltd

Abbott India Ltd

Aarti Drugs Ltd

Table of Contents

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1 - About the Company

Lupin Ltd - Key Facts

Lupin Ltd - Key Employees

Lupin Ltd - Key Employee Biographies

Lupin Ltd - Major Products and Services

Lupin Ltd - History

Lupin Ltd - Company Statement

Lupin Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Joint Venture

Section 2 Company Analysis

Company Overview

Lupin Ltd - Business Description

R&D Overview

Lupin Ltd - Corporate Strategy

Lupin Ltd - SWOT Analysis

SWOT Analysis - Overview

Lupin Ltd - Strengths

Lupin Ltd - Weaknesses

Lupin Ltd - Opportunities

Lupin Ltd - Threats

Lupin Ltd - Key Competitors

Section 3 Company Financial Ratios

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

Section 4 Company’s Lifesciences Financial Deals and Alliances

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Lupin Ltd, Recent Deals Summary

Section 5 Company’s Recent Developments

Jun 10, 2019: Lupin recently announced the appointment of Mr. Sunil Makharia as interim chief financial officer and key managerial personnel.

Jun 04, 2019: Japan's PMDA completes inspection of lupin' s Mandideep facility (Unit-2)

May 27, 2019: U.S. FDA classifies the inspection of Lupin's Goa facility as OAI

May 15, 2019: U.S. FDA completes inspection of Lupin’s Aurangabad facility

May 15, 2019: Lupin announces fiscal year 2019 results

May 14, 2019: Lupin receives EIR for Pharmacovigilance inspection from the U.S. FDA

Apr 23, 2019: U.S. FDA classifies the inspection of Lupin's Pithampur (Indore) Unit-2 facility as OAI

Apr 03, 2019: Lupin Bioresearch Centre completes fifth successful U.S. FDA inspection

Apr 02, 2019: Lupin's Pithampur unit-3 receives EIR from U.S. FDA

Apr 01, 2019: lupin names Ms. Christine Mundkur as an independent director

Section 6 Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List of Tables

List of Tables

Lupin Ltd, Key Facts

Lupin Ltd, Key Employees

Lupin Ltd, Key Employee Biographies

Lupin Ltd, Major Products and Services

Lupin Ltd, History

Lupin Ltd, Other Locations

Lupin Ltd, Subsidiaries

Lupin Ltd, Joint Venture

Lupin Ltd, Key Competitors

Lupin Ltd, Ratios based on current share price

Lupin Ltd, Annual Ratios

Lupin Ltd, Annual Ratios (Cont…1)

Lupin Ltd, Annual Ratios (Cont…2)

Lupin Ltd, Interim Ratios

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Lupin Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

List of Figures

List of Figures

Lupin Ltd, Performance Chart (2015 – 2019)

Lupin Ltd, Ratio Charts

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

    Pricing

Quick Buy
Add to basket Enquire before buying

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports